Invivyd News and Activities

Invivyd is a company listed under the stock ticker IVVD (US).

View the org chart displaying its 21 main executives

Most searched biographies at Invivyd

• Tamsin Berry, Director
• Kevin Mclaughlin, Director
• Paul Bolno, Director

Popular executive movements at Invivyd

• Michael Mina has joined the company as Chief Medical Officer  (posted on March 6 2026).

Create your alert
to follow the executive moves at Invivyd.

Invivyd has 2,425 competitors including Lonza (Switzerland), Vertex Pharmaceuticals (United States (USA)) and Eurofins (Luxembourg).

Popular M&A news in Biotechnology

• Chemomab and Scipher Medicine have announced they will merge  (posted on July 13 2026)..
• Apnimed has filed its IPO. Its stock ticker will be APMD. (posted on July 13 2026).
• The new name of EG 427 is Cyllene Therapeutics. (posted on July 10 2026).

Popular contacts in Biotechnology

• Jakob Uszkoreit - Co-Founder and Chief Executive Officer at Inceptive
• Jan Van de Winkel - President and Chief Executive Officer at Genmab
• Robert Gould - Board Member at Fulcrum Therapeutics

Learn more about the Biotechnology industry

Press releases by Invivyd

• Invivyd Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | Invivyd
• Invivyd Announces Receipt of Twelve Months’ Advanced Notice of Emergency Use Authorization (EUA) Termination for PEMGARDA® and Provides an Update on Next Steps with the U.S. FDA | Invivyd
• Invivyd Announces Completion of Enrollment in Phase 3 LIBERTY Trial Evaluating VYD2311 Antibody Versus mRNA COVID-19 Vaccine | Invivyd
• Invivyd Announces First Participants Dosed in LIBERTY, a Phase 3 Clinical Trial to Evaluate the Safety and Tolerability of VYD2311 Antibody Versus mRNA COVID Vaccine and to Characterize the Safety and Immunology of Antibody and mRNA Vaccine Co-Administrat
• Invivyd Announces Completion of Enrollment in Upsized DECLARATION Clinical Trial, a Phase 3 Pivotal Study of VYD2311, an Investigational Antibody to Prevent COVID | Invivyd
• Invivyd Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | Invivyd
• Invivyd to Participate in Upcoming Investor Events | Invivyd
• Invivyd Reports First Quarter 2026 Financial Results and Recent Business Highlights | Invivyd
• Invivyd and Collaborators Author New Manuscript Evaluating Early Tolerability of COVID Monoclonal Antibody and Comparing Results to COVID Vaccination | Invivyd
• Invivyd to Host First Quarter 2026 Financial Results and Corporate Update Call on May 14, 2026 | Invivyd
• View more press releases Close

Social media about Invivyd

• Invivyd on Wikipedia, Google News & Yahoo Finance
• Invivyd on LinkedIn, X (Twitter) & YouTube